BICX.OIDBiocorrx INC
10-Q: BioCorRx Inc. Reports First Quarter 2024 Results Amidst Ongoing Development Efforts
Sentiment:
Quarterly Report
BioCorRx Inc. reported its first quarter 2024 financial results, showing a decrease in revenue and an increase in net loss, while continuing to advance its addiction treatment solutions and pharmaceutical development.
Capital raiseThe company intends to raise additional capital through private placements of debt and equity securities.The company is dependent on raising additional capital to implement its business plan.
Worse than expectedThe company's revenue decreased significantly, and the net loss increased compared to the same period last year.Interest expenses increased substantially, impacting the bottom line.Grant income decreased, affecting the company's overall financial performance.
Summary
- BioCorRx Inc. reported a net loss of $1.24 million for the first quarter of 2024, compared to a net loss of $1.01 million for the same period in 2023.
- The company's revenue decreased significantly to $3,620 in Q1 2024 from $40,442 in Q1 2023, primarily due to a decrease in project support and distribution rights income.
- Operating expenses decreased to $972,312 in Q1 2024 from $1,096,757 in Q1 2023, mainly due to reduced payroll, consulting, and research and development costs.
- Interest expenses increased substantially to $181,820 in Q1 2024 from $26,040 in Q1 2023, due to new debt and increased interest rates on existing debt.
- Grant income decreased to $112,963 in Q1 2024 from $241,149 in Q1 2023, reflecting changes in the timing of grant reimbursements.
- The company's cash balance was $101,080 as of March 31, 2024, with a working capital deficit of $7.02 million.
- BioCorRx Pharmaceuticals Inc., a subsidiary, received a $11 million grant from the National Institutes of Health for research into a methamphetamine use disorder treatment.
Sentiment
Score: 3
Explanation: The document presents a concerning financial picture with significant revenue decline, increased losses, and a going concern warning. While the grant is a positive development, the overall sentiment is negative due to the company's financial instability and operational challenges.
Positives
- Operating expenses decreased by $124,445 year-over-year, indicating cost-cutting measures.
- BioCorRx Pharmaceuticals Inc. secured an $11 million grant from the NIH, providing significant funding for research.
- The company continues to develop its addiction treatment solutions and pharmaceutical products.
Negatives
- Revenue decreased by 91% year-over-year, indicating a significant decline in sales.
- The net loss increased to $1.24 million in Q1 2024, compared to $1.01 million in Q1 2023.
- Interest expenses increased substantially, impacting the bottom line.
- Grant income decreased, affecting the company's overall financial performance.
- The company has a working capital deficit of $7.02 million, raising concerns about its financial stability.
Risks
- The company's ability to continue as a going concern is in doubt due to its working capital deficit and accumulated losses.
- The company is dependent on raising additional capital through private placements, which may not be available on acceptable terms.
- The company faces risks related to the development and regulatory approval of its pharmaceutical products.
- The company's reliance on a few customers for the majority of its revenue creates a concentration risk.
- The company has identified material weaknesses in its internal control over financial reporting.
Future Outlook
The company intends to raise additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations.
Management Comments
- Management believes that its current cash on hand will not be sufficient to fund its projected operating requirements for the next twelve months since the date of the issuance of the financial statements.
- Management has concluded that financial statements, and other financial information included in this quarterly report, fairly present in all material respects our financial condition, results of operations, and cash flows as of and for the periods presented in this quarterly report.
Industry Context
The company operates in the addiction treatment and pharmaceutical development industries, which are characterized by high regulatory hurdles and significant research and development costs. The company's focus on naltrexone implants for opioid and alcohol use disorders aligns with the growing need for effective and long-lasting treatment options. The recent grant for methamphetamine use disorder research highlights the company's efforts to address emerging substance abuse challenges.
Comparison to Industry Standards
- BioCorRx's revenue decline is concerning compared to industry peers, many of whom are experiencing growth in the addiction treatment sector.
- The company's high operating expenses and significant net losses are not uncommon for early-stage pharmaceutical companies, but the magnitude of the losses is substantial.
- The $11 million grant is a positive development, but the company's ability to manage its cash flow and achieve profitability remains a significant challenge.
- Compared to companies like Alkermes, which markets Vivitrol, BioCorRx is still in the development phase and has not yet achieved commercial success.
- The company's reliance on private financing is a common practice for early-stage biotech companies, but the uncertainty of securing future funding is a significant risk.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Interim President | NA | Lou Lucido | 2024-01-05 | Interim appointment |
| President | Brady Granier | Lou Lucido | 2024-02-01 | Brady Granier resigned |
| Board Member | Brady Granier | NA | 2024-03-31 | Brady Granier resigned |
| Board Member | Harsha Murthy | NA | 2024-04-02 | Harsha Murthy resigned |
Legal Proceedings
- The company is involved in ongoing legal proceedings related to a 2019 litigation with Pellecome, where the company was ordered to pay costs and attorneys fees of $332,503, plus accrued interest.
Related Party Transactions
- The company has significant related party transactions, including advances and promissory notes with directors and officers.
- The company has a royalty agreement with a related party, which is being amortized as interest expense.
- The company entered into exchange agreements with Mr. Lucido and Ms. Felix to exchange debt for shares of restricted common stock.
Stakeholder Impact
- Shareholders face significant risk due to the company's financial instability and going concern warning.
- Employees may be affected by potential cost-cutting measures or scaling back of operations.
- Customers may experience disruptions in service if the company faces financial difficulties.
- Creditors face the risk of non-payment due to the company's financial challenges.
Next Steps
- The company needs to secure additional funding to continue operations and development efforts.
- The company must manage its cash flow and reduce operating expenses.
- The company needs to advance its pharmaceutical development programs and seek regulatory approvals.
- The company needs to address the material weaknesses in its internal control over financial reporting.
Key Dates
| Date | Description |
|---|---|
| 2013-01-22 | Unsecured promissory note issued to Kent Emry. |
| 2014-11-13 | Board of Directors authorized and approved the adoption of the 2014 Stock Option Plan. |
| 2015-12-10 | Company entered into a royalty agreement with Alpine Creek Capital Partners LLC. |
| 2016-06-15 | Board of Directors authorized and approved the adoption of the 2016 Equity Incentive Plan. |
| 2016-07-28 | BioCorRx Inc. formed BioCorRx Pharmaceuticals, Inc. |
| 2018-05-15 | Board of Directors approved and adopted the BioCorRx Inc. 2018 Equity Incentive Plan. |
| 2018-10-12 | BioCorRx Pharmaceuticals Inc. acquired six patent families. |
| 2019-01-17 | Company received a Notice of Award from the United States Department of Health and Human Services for a grant from the National Institutes of Health (NIH). |
| 2019-05-24 | Company entered into a Master Services Agreement with Charles River Laboratories, Inc. |
| 2019-09-30 | Company entered into a Conversion Agreement with BICX Holding Company LLC. |
| 2020-07-17 | Company executed loan documents for an Economic Injury Disaster Loan. |
| 2020-10-31 | Company entered into a management services agreement with Joseph DeSanto MD, Inc. |
| 2021-08-27 | Company received a Notice of Award from the United States Department of Health and Human Services for a grant from National Institute on Drug Abuse for BICX104. |
| 2021-09-09 | Company issued an unsecured promissory note payable to Kent Emry. |
| 2021-09-22 | BioCorRx Inc. and BioCorRx Pharmaceuticals, Inc. entered into a Inter-Company License Agreement. |
| 2022-01-11 | Company entered into a Master Clinical Trial Agreement with Orange County Research Center. |
| 2022-04-22 | Board of Directors approved and adopted the BioCorRx Inc. 2022 Equity Incentive Plan. |
| 2022-06-08 | Company issued a warrant that entitles the third party to purchase 48,309 common shares due to the loan default. |
| 2022-10-06 | Company issued an unsecured promissory note payable to a third party. |
| 2023-01-25 | Company issued an unsecured promissory note payable to a third party. |
| 2023-03-16 | Company received advances from Mr. Lucido. |
| 2023-04-03 | Company entered into the Louis 2023 Exchange Agreement. |
| 2023-08-29 | Company issued an unsecured promissory note payable to Louis C Lucido. |
| 2023-09-06 | Company issued an unsecured promissory note payable to one third party. |
| 2023-10-30 | Board approved Brady Graniers request for a paid administrative leave of absence. |
| 2023-11-09 | Company entered into Subscription Agreements with the J and R Galligan Revocable Trust and Louis C Lucido. |
| 2023-11-10 | Company issued an unsecured promissory note payable to a third party. |
| 2023-12-08 | Company issued an unsecured promissory note payable to a third party. |
| 2023-12-29 | Brady Granier submitted his letter of resignation as President of the Company and Chief Executive Officer of BioCorRx Pharmaceuticals. |
| 2024-01-05 | California Superior Court for Orange County entered an amended judgement of $332,503 in favor of Pellecome. |
| 2024-01-05 | Company's board of directors appointed Lou Lucido as Interim President. |
| 2024-01-26 | Interest rate increased to 20% on the promissory note issued on January 25, 2023 due to default. |
| 2024-02-01 | Lou Lucido transitioned to President. |
| 2024-02-22 | BioCorRx Pharmaceuticals Inc. was awarded a grant of $11,029,977 from the National Institutes of Healths National Institute on Drug Abuse. |
| 2024-03-08 | Company entered into an amendment agreement to a promissory note issued on November 10, 2023. |
| 2024-03-14 | Company issued an unsecured promissory note payable to a third party. |
| 2024-03-25 | Company entered into an amendment agreement to a promissory note issued on December 8, 2023. |
| 2024-03-29 | Mr. Granier submitted his letter of resignation from his position as a member of the Board. |
| 2024-03-31 | End of the reporting period for the quarterly report. |
| 2024-04-02 | Harsha Murthy submitted his letter of resignation from his position as a member of the Board. |
| 2024-04-24 | Company and Mr. Lucido entered into an exchange agreement. |
| 2024-04-24 | Company and Ms. Felix entered into an exchange agreement. |
| 2024-05-14 | Date of common stock outstanding. |
| 2024-05-15 | Date of the report. |
Keywords
BioCorRx, addiction treatment, naltrexone implant, BICX104, opioid use disorder, methamphetamine use disorder, financial results, grant funding, pharmaceutical development, clinical trials
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.